Price to trailing twelve month operating cash flow for LCI is currently 2.78, higher than merely 11.67% of US stocks with positive operating cash flow.
LCI's price/sales ratio is 0.51; that's higher than the P/S ratio of only 12.64% of US stocks.
Lannett Co Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 25.52%, greater than the shareholder yield of 92.05% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Lannett Co Inc, a group of peers worth examining would be SPR, ENVA, GOGO, FCEL, and HL.
Lannett Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.
LCI Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for LCI, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lannett Co Inc ranked in the 46th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 22%. As for the metrics that stood out in our discounted cash flow analysis of Lannett Co Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 0.15 -- which is good for besting just 24.31% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.02%; that's greater than merely 22.2% of US stocks we're applying DCF forecasting to.
28% of the company's capital comes from equity, which is greater than just 7.8% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as LCI, try LMAT, INBP, IQV, PAHC, and BDX.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Lannett Company, Inc. New York, December 15, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Lannett Company, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
New Delhi: Drug firm Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease. The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 mg, 5 mg and 10 mg of Lannett Company, Inc. In a regulatory filing, Alembic Pharmaceuticals said "it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg". Metolazone tablets are indicated for the treatment of salt and water retention including edema accompanying congestive heart failure, edema accompanying renal diseases, including ...